Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
NSABP Foundation
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00321828 | https://clinicaltrials.gov/study/NCT00856492 | https://clinicaltrials.gov/study/NCT07334301 | https://clinicaltrials.gov/study/NCT04689347 | https://clinicaltrials.gov/study/NCT00055913 | https://clinicaltrials.gov/study/NCT00365144 | https://clinicaltrials.gov/study/NCT00162669 | https://clinicaltrials.gov/study/NCT00345761 | https://clinicaltrials.gov/study/NCT01609790 | https://clinicaltrials.gov/study/NCT01222715 | https://clinicaltrials.gov/study/NCT03007407 | https://clinicaltrials.gov/study/NCT04245514 | https://clinicaltrials.gov/study/NCT02431559 | https://clinicaltrials.gov/study/NCT02938793
Assets
Linked programs
- bevacizumab: Results Not Found Signal (4/5)
- durvalumab: Registry Stop Signal (4/5)